Medicines

WORLDWIDE BUSINESS DEVELOPMENT

Forward Thinking

WORLDWIDE BUSINESS DEVELOPMENT

We are searching for Forward Thinking companies to explore new ideas together

Email: ww.bd@gsk.com

printed on recycled stock

06012011

ww.bd@gsk.com

Working with a Proven Collaborator

GSK’s unique R&D organization has successfully worked in a diverse range of collaborations and is absolutely committed to finding talent, ideas, technologies, and new medicines outside of GSK. The Business Development team is experienced at building progressive external relationships that are strong, mutually beneficial collaborations including: OPTION-BASED COLLABORATIONS:

We believe these unique business models truly nurture innovation. We seek organizations that have a robust discovery engine and the capability of developing compounds to clinical proof of concept, at which point GSK would have the option for further development and commercialization.

“ A wellspring of innovation exists in the global effort to discover new ways to treat and prevent disease. We recognize that leading-edge science lies both within and outside of GSK’s R&D labs. Externalization is key to our R&D strategy and we have a solid track record of successful collaborations that ultimately help bring new medicines of value to improve patients’ lives.”

IAN TOMLINSON Senior Vice President, Worldwide Business Development & Biopharmaceuticals R&D

We are looking for innovation wherever it may originate

LATE-STAGE LICENSING:

Over the past ten years, GSK signed more late-stage collaborations than anyone else in the industry. In fact, a large portion of our late-stage pipeline is a direct result of these collaborations.

ACQUISITIONS:i t e We i nv

yo u t o c o n t a c t u s :

We have completed a number of acquisitions over the past four years and believe in keeping the innovative spirit as part of our approach to acquisitions.

LESLIE BOYD Vice President, Scientific Licensing leslie.2.boyd@gsk.com...